{"id":"nab-paclitaxel-trastuzumab-patuzumab","safety":{"commonSideEffects":[{"rate":"High (> 40%)","effect":"Neutropenia"},{"rate":"Moderate (20-40%)","effect":"Fatigue"},{"rate":"Moderate (20-40%)","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Nab-paclitaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. Trastuzumab and pertuzumab, on the other hand, bind to the HER2 protein on the surface of cancer cells, preventing the growth and proliferation of these cells.","oneSentence":"Nab-paclitaxel is a microtubule inhibitor that disrupts cell division, while trastuzumab and pertuzumab are monoclonal antibodies that target the HER2 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:33.181Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of HER2-positive breast cancer"},{"name":"Metastatic breast cancer with HER2 overexpression"}]},"trialDetails":[{"nctId":"NCT07057427","phase":"PHASE3","title":"Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-24","conditions":"Breast Cancer","enrollment":812},{"nctId":"NCT05918328","phase":"PHASE2","title":"Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-05-03","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":610},{"nctId":"NCT04547907","phase":"PHASE3","title":"A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2020-09-18","conditions":"Breast Cancer,HER2-positive","enrollment":688},{"nctId":"NCT05429684","phase":"PHASE3","title":"Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-01-01","conditions":"HER2+ Breast Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["nab-PHP regimen group"],"phase":"phase_3","status":"active","brandName":"Nab-paclitaxel+ trastuzumab+ patuzumab","genericName":"Nab-paclitaxel+ trastuzumab+ patuzumab","companyName":"Henan Cancer Hospital","companyId":"henan-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nab-paclitaxel is a microtubule inhibitor that disrupts cell division, while trastuzumab and pertuzumab are monoclonal antibodies that target the HER2 protein. Used for Adjuvant treatment of HER2-positive breast cancer, Metastatic breast cancer with HER2 overexpression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}